Can the shingles vaccine protect those with autoimmune conditions?
NCT ID NCT07280741
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether the shingles vaccine (RZV) works and is safe for adults with autoimmune rheumatic diseases like rheumatoid arthritis or lupus who are taking immune-suppressing drugs. Two hundred participants will receive two doses of the vaccine. Researchers will measure antibody levels and track shingles cases to see if the vaccine provides protection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Recombinant Zoster Vaccine (Shingrix)
- What this could lead to
- If successful, this could show that the shingles vaccine is effective and safe for people with autoimmune rheumatic diseases on immunomodulators, helping prevent a painful condition.
- What could go wrong
- This is a phase 4 trial with 200 participants, so results may not apply to everyone. The vaccine might be less effective in people on certain immune-suppressing drugs, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE RHEUMATIC DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital das Clínicas
RECRUITINGSão Paulo, São Paulo, 05403-010, Brazil
More trials for these conditions
Other studies related to the condition(s) this trial covers.